Vira Regen

Vira Regen is a defense-funded regenerative biotech company pioneering electrogenetics—a new class of bioelectronic medicine that uses gene-targeted electrical stimulation to precisely modulate regenerative pathways and enhance the body's natural healing response. Its lead product, OsteoVolt, is the first frontline, noninvasive bioelectronic bone regeneration therapy designed to be applied within 1–4 days after injury to accelerate fracture healing. The system combines a wearable limb brace with a preprogrammed stimulator that delivers proprietary, frequency-specific electrical waveforms using a capacitive coupling approach to selectively regulate key osteogenic gene cascades, including TGF-β, OPG, BMP9, and other critical mediators of bone regeneration. Vira Regen has successfully completed a 30-animal preclinical study demonstrating approximately ~50% faster bone healing compared with controls, secured ~$2 million in non-dilutive funding through the Department of War's Medical Technology Enterprise Consortium (MTEC), and filed two patents covering its novel bioelectric stimulation platform. The company is now raising a $3 million seed round to support GLP large-animal studies, regulatory activities, and an initial clinical pilot, positioning OsteoVolt for FDA clearance through the Class II 510(k) pathway while expanding its electrogenetic platform toward additional musculoskeletal, orthopedic, cancer, and regenerative medicine indications.